文献速递妇科

含贝伐珠单抗方案治疗复发性低级别浆液性卵巢癌或腹膜癌的活性:单机构经验

Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
PubMed 文献 · Gynecol Oncol · 2017-01-27

单机构回顾性研究纳入2007至2016年MD安德森癌症中心40例复发性低级别浆液性卵巢癌或腹膜癌患者,共接受45个含贝伐珠单抗方案。总体缓解率(完全缓解+部分缓解)为47.5%,临床获益率77.5%,中位无进展生存期10.2个月(95%CI 7.9, 12.4),中位总生存期34.6个月(95%CI 29.5, 39.7);15例因毒性停用贝伐珠单抗。作者认为贝伐珠单抗在复发性低级别卵巢癌中有活性,应视为治疗选择,并需进一步研究最佳联合化疗药物。

要点

  • 含贝伐珠单抗方案总体缓解率(完全缓解+部分缓解)为47.5%。
  • 中位无进展生存期10.2个月(95%CI 7.9, 12.4),中位总生存期34.6个月(95%CI 29.5, 39.7)。
  • 15例患者因毒性停用贝伐珠单抗。

核心结论

  • 贝伐珠单抗(最常与化疗联合)在复发性低级别卵巢癌中具有活性,应被视为这些患者的治疗选择。
  • 需要进一步研究与贝伐珠单抗联合的最有效化疗药物。

研究设计与样本

  • 单机构回顾性研究,评估2007至2016年MD安德森癌症中心接受贝伐珠单抗治疗的复发性低级别浆液性卵巢癌或腹膜癌患者。
  • 共40例患者,接受45个独立「患者-方案」。
  • 大多数患者接受贝伐珠单抗联合化疗。
  • 研究终点包括最佳缓解、中位无进展生存期、中位总生存期和毒性。

主要发现

  • 完全缓解(CR)见于7.5%,部分缓解(PR)40%,疾病稳定(SD)30%。
  • 疾病进展9例(22.5%)。
  • 总体缓解率(CR+PR)为47.5%,临床获益(CR+PR+SD)为77.5%。
  • 中位无进展生存期10.2个月(95%CI 7.9, 12.4),中位总生存期34.6个月(95%CI 29.5, 39.7)。
  • 15例患者因毒性停用贝伐珠单抗。

临床怎么用

  • 作者认为,贝伐珠单抗(最常与化疗联合)应被视为复发性低级别卵巢癌患者的治疗选择。
  • 作者提出需要进一步研究与贝伐珠单抗联合的最有效化疗药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum. METHODS: This single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity. RESULTS: Forty patients received 45 separate "patient-regimens." Most received bevacizumab in combination with chemotherapy. Complete response (CR) was seen in 7.5%, while 40% had partial responses (PR) and 30% achieved stable disease (SD). Disease progression occurred in nine patients (22.5%). Overall response rate (CR+PR) to bevacizumab-containing regimens was 47.5%. Clinical benefit (CR+PR+SD) was seen in 77.5% of patients. Median progression free survival was 10.2months (95% CI 7.9, 12.4). Median overall survival was 34.6months (95% CI 29.5, 39.7). Fifteen patients discontinued bevacizumab related to toxicity. CONCLUSIONS: Bevacizumab, most often in combination with chemotherapy, has activity in recurrent low-grade ovarian cancer and should be considered a treatment option for these patients. Further investigation into the most effective chemotherapeutic agent in combination with bevacizumab is warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dalton HJ, Fleming ND, Sun CC, et al. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017. PMID: 28139261. doi:10.1016/j.ygyno.2017.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。